Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Front Endocrinol (Lausanne). 2022 Jul 12;13:924841. doi: 10.3389/fendo.2022.924841. eCollection 2022.
Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon, presents a considerable therapeutic challenge with poor long-term outcomes. Currently, tyrosine kinase inhibitors are the mainstay of treatment for advanced RAIR-DTC patients. However, these agents are associated with a multitude of adverse events with resultant deterioration in the quality-of-life of the patients. Targeted theranostic approaches with radiolabelled integrin binders and fibroblast activation protein- (FAP)-inhibitors seem to have a promising role in the management of such patients. This mini-review focuses on these novel theranostic strategies in RAIR-DTC, with emphasis on recent advances, existing challenges, and future directions.
放射性碘难治性分化型甲状腺癌（RAIR-DTC）虽不常见，但治疗极具挑战性，长期预后较差。目前，酪氨酸激酶抑制剂是晚期 RAIR-DTC 患者的主要治疗药物。然而，这些药物会引起多种不良反应，导致患者生活质量下降。放射性标记的整合素结合剂和纤维母细胞激活蛋白（FAP）抑制剂的靶向治疗方法在这类患者的治疗中似乎具有广阔的应用前景。本综述聚焦于 RAIR-DTC 中的这些新型治疗策略，重点介绍最新进展、现有挑战和未来方向。
